BE700047A - - Google Patents

Info

Publication number: BE700047A
Authority: BE; Belgium
Prior art keywords: pharmaceutical composition; treatment; disease; patient; taurine
Prior art date: 1966-06-18

Application number

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1966-06-18

Filing date

1967-06-16

Publication date

1967-12-01

1967-06-16 Application filed filed Critical

1967-12-01 Publication of BE700047A publication Critical patent/BE700047A/fr

Links

XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 85
229960003080 taurine Drugs 0.000 claims description 43
238000011282 treatment Methods 0.000 claims description 41
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
201000010099 disease Diseases 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 16
210000001367 artery Anatomy 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 14
238000000034 method Methods 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 9
200000000007 Arterial disease Diseases 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
150000007529 inorganic bases Chemical class 0.000 claims description 5
230000000287 tissue oxygenation Effects 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 4
150000007530 organic bases Chemical class 0.000 claims description 4
239000003981 vehicle Substances 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
208000003782 Raynaud disease Diseases 0.000 claims description 3
208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
238000001361 intraarterial administration Methods 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 2
239000000203 mixture Substances 0.000 description 26
241001465754 Metazoa Species 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
230000000694 effects Effects 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000008280 blood Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000000470 constituent Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 7
208000002193 Pain Diseases 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
230000007423 decrease Effects 0.000 description 6
210000002683 foot Anatomy 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
230000036407 pain Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
208000025865 Ulcer Diseases 0.000 description 5
230000017531 blood circulation Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000006872 improvement Effects 0.000 description 5
238000001802 infusion Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
239000006188 syrup Substances 0.000 description 5
235000020357 syrup Nutrition 0.000 description 5
231100000397 ulcer Toxicity 0.000 description 5
241000700159 Rattus Species 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
238000010171 animal model Methods 0.000 description 4
210000000941 bile Anatomy 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
HOHIAEPXOHCCGW-UHFFFAOYSA-N 2-aminoethanesulfonic acid Chemical compound NCCS(O)(=O)=O.NCCS(O)(=O)=O HOHIAEPXOHCCGW-UHFFFAOYSA-N 0.000 description 3
206010017577 Gait disturbance Diseases 0.000 description 3
206010022562 Intermittent claudication Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010039710 Scleroderma Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
230000006870 function Effects 0.000 description 3
230000036284 oxygen consumption Effects 0.000 description 3
239000008196 pharmacological composition Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
206010008479 Chest Pain Diseases 0.000 description 2
239000004380 Cholic acid Substances 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
229920000715 Mucilage Polymers 0.000 description 2
206010028594 Myocardial fibrosis Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000019416 cholic acid Nutrition 0.000 description 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
229960002471 cholic acid Drugs 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
208000024980 claudication Diseases 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000007574 infarction Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
239000001095 magnesium carbonate Substances 0.000 description 2
229910000021 magnesium carbonate Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
-1 taurine compound Chemical class 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000001457 vasomotor Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
244000208874 Althaea officinalis Species 0.000 description 1
235000006576 Althaea officinalis Nutrition 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010052895 Coronary artery insufficiency Diseases 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
244000303040 Glycyrrhiza glabra Species 0.000 description 1
235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
244000130592 Hibiscus syriacus Species 0.000 description 1
235000018081 Hibiscus syriacus Nutrition 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000005230 Leg Ulcer Diseases 0.000 description 1
241000237536 Mytilus edulis Species 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
241000237502 Ostreidae Species 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
239000011575 calcium Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000001463 effect on reproduction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000030175 lameness Diseases 0.000 description 1
235000011477 liquorice Nutrition 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000013310 margarine Nutrition 0.000 description 1
239000003264 margarine Substances 0.000 description 1
235000001035 marshmallow Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
235000020638 mussel Nutrition 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
235000020636 oyster Nutrition 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
208000023482 precordial pain Diseases 0.000 description 1
239000000047 product Substances 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
230000009758 senescence Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
235000020238 sunflower seed Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940046664 taurine 500 mg Drugs 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000002465 tibial artery Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000010497 wheat germ oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BE700047D 1966-06-18 1967-06-16 BE700047A (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT3523166		1966-06-18

Publications (1)

Publication Number	Publication Date
BE700047A true BE700047A (de)	1967-12-01

Family

ID=11241178

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE700047D BE700047A (de)	1966-06-18	1967-06-16

Country Status (3)

Country	Link
BE (1)	BE700047A (de)
FR (1)	FR7241M (de)
NL (1)	NL6708311A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69125216T2 (de) *	1990-07-19	1997-09-25	Nippon Zoki Pharmaceutical Co	Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
US5582839A (en) *	1995-04-18	1996-12-10	Nutrition 21	Magnesium taurate and other mineral taurates
US6099869A (en) *	1995-04-18	2000-08-08	Nutrition 21	Calcium taurate and antihypertensive drug for hypertension

1967
- 1967-06-15 NL NL6708311A patent/NL6708311A/xx unknown
- 1967-06-15 FR FR110539A patent/FR7241M/fr not_active Expired
- 1967-06-16 BE BE700047D patent/BE700047A/fr unknown

Also Published As

Publication number	Publication date
FR7241M (de)	1969-09-08
NL6708311A (de)	1967-12-19

Publication	Publication Date	Title
JP5690261B2 (ja)	2015-03-25	β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
EP0316993B1 (de)	1991-07-24	Pharmazeutische Zusammensetzungen mit Gehalt an einem Derivat der 3-Hydroxy-Buttersäure, ausgewählt aus den Oligomeren dieser Säure und den Estern dieser Säure oder dieser Oligomere mit dem 1,3-Butan-diol
JPH07507569A (ja)	1995-08-24	ヒトの窒素保持の促進方法
EP1283708B1 (de)	2005-08-03	Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
JPH09512552A (ja)	1997-12-16	腎疾患および不全の治療方法ならびに組成物
JPH09500144A (ja)	1997-01-07	心疾患の患者を処理する方法
FR2530468A1 (fr)	1984-01-27	Composition analgesique et anti-inflammatoire contenant de l'ibuprofen
CN1505505A (zh)	2004-06-16	辅酶q作为活性成分的经粘膜给药的组合物
HU184219B (en)	1984-07-30	Process for producing pharmaceutical compositions of aggragati on-inhiaiting activity
FR2482588A1 (fr)	1981-11-20	Composition pharmaceutique pour le traitement du diabete sucre juvenile
KR100304312B1 (ko)	2001-11-22	아연이보충된전립선추출물
BE700047A (de)	1967-12-01
EP0146474A2 (de)	1985-06-26	Nährlösung enthaltend alpha-Ketoisocapronsäure oder eines ihrer Salze
EP1815858A2 (de)	2007-08-08	Verbindung zwischen einem Liganden von durch Proliferatoren von Peroxisomen aktivierten Rezeptoren und einem Antioxidationsmittel und die diese enthaltenden pharmazeutischen Zusammensetzungen
EP2397136A1 (de)	2011-12-21	Entzündungshemmende Zusammensetzung
FR2471189A1 (fr)	1981-06-19	Procede de preparation d'un agent anti-tumoral comprenant un composant cellulaire de streptococcus pyogenes
JP5187935B2 (ja)	2013-04-24	羅漢果エキスを含有する創傷治癒促進組成物と適用方法
FR2843883A1 (fr)	2004-03-05	Extraits de sangsues pour psoriasis
RU2022561C1 (ru)	1994-11-15	Противоишемическое средство
CN1756536A (zh)	2006-04-05	用于治疗与年龄相关的疾病的组合物与方法
JPH08253415A (ja)	1996-10-01	抗動脈硬化治療剤
BE896621A (fr)	1983-11-03	Nouvelle utilisation therapeutique d'analogues de prostaglandines
FR2842425A1 (fr)	2004-01-23	Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse
JP2003335665A (ja)	2003-11-25	生体内ビタミンｃレベル調節用組成物
JP2023169632A (ja)	2023-11-30	心不全予防用食品および心不全予防用医薬組成物